Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate.

Ther Clin Risk Manag · 2008 · PMC2503651 · PMID 18728705

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Interestingly, there were more responses in the higher dose group (61% vs 47%), but this did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.